OmicsDI
Toggle navigation
Browse
Submit Data
Databases
API
Help
Advanced
Search
19
Results
Show all
Save search
Copy query
Show results for
Genomics
(15)
Unknown
(4)
Organisms
Homo sapiens
(15)
Repository
EGA
(15)
Technology Type
Illumina 15K
(8)
Illumina_670k - Illuminus, Affymetrix 6.0, Illumina 1.2M
(1)
Publication Date
Release Date
2021
(3)
2012
(1)
Previous
page
1 / 2
You're on page
1
page
2
Next
page
Sort
by:
Relevance
Page size
10
AS
WTCCC2 project samples from Ankylosing spondylitis Cohort
EGAD00010000150
|
EGA
Cite
Genomewide association studies in ankylosing spondylitis
The aim of this study was to identify genes associated with ankylosing spondylitis susceptibility in British and Australian individuals of European descent.
EGAS00000000104
|
EGA
Cite
ATD
WTCCC1 project Autoimmune Thyroid Disease (ATD) samples
EGAD00000000011
|
EGA
Cite
BC
WTCCC1 project Breast cancer (BC) samples
EGAD00000000013
|
EGA
Cite
MS
WTCCC1 project Multiple Sclerosis (MS) samples
EGAD00000000012
|
EGA
Cite
WTCCC2 Ankylosing spondylitis cases - individual
WTCCC1 project Ankylosing Spondylitis (AS) samples
EGAD00000000010
|
EGA
Cite
58C
WTCCC1 project samples from 1958 British Birth Cohort
EGAD00000000014
|
EGA
Cite
WTCCC case-control study for Autoimmune Thyroid Disease
WTCCC genome-wide case-control association study for Autoimmune Thyroid Disease (ATD) using the 1958 British Birth Cohort collection as controls.
EGAS00000000020
|
EGA
Cite
WTCCC case-control study for Ankylosing Spondylitis
WTCCC genome-wide case-control association study for Ankylosing Spondylitis (AS) using the 1958 British Birth Cohort collection as controls.
EGAS00000000018
|
EGA
Cite
WTCCC case-control study for Multiple Sclerosis
WTCCC genome-wide case-control association study for Multiple Sclerosis (MS) using the 1958 British Birth Cohort collection as controls.
EGAS00000000022
|
EGA
Cite
Previous
page
1 / 2
You're on page
1
page
2
Next
page
Sort
by:
Relevance
Page size
10
OmicsDI
is part of the ELIXIR infrastructure
OmicsDI is an Elixir interoperability service.
Learn more ›
Tweets